Morgan Stanley raised the firm’s price target on GSK (GSK) to 1,600 GBp from 1,500 GBp and keeps an Underweight rating on the shares.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GSK:
- Trump Trade: Trump administration moves to end pharma trade probe
- Trump administration moves to end U.S. pharma trade probe, Endpoints News says
- GSK Advances New First-in-Human Prostate Cancer Drug Into Early Clinical Testing
- Summit Therapeutics. GSK collaborate on trial of ivonescimab
- Tempus AI (TEM) Tops $1.1B in Total Contract Value as Pharma Demand for AI Tools Surges